LEXINGTON, Mass. (AP) — Cubist Pharmaceuticals said Wednesday that regulators gave a new approval to its antibiotic Cubicin,
allowing Cubist to market a two-minute injection version of the drug.
The company said the Food and Drug Administration approved marketing of
once-daily, two-minute IV injections of Cubicin, which treats complex skin
infections like staph injections and the drug-resistant MRSA “superbug.” Cubist
was originally approved in 2003 as a 30-minute infusion.
“Having to spend only 2 minutes a day receiving CUBICIN, especially for
patients in the outpatient setting, minimizes the impact that IV therapy has on
their daily activities,” Cubist President and CEO Michael W. Bonney said in a
statement.
